" class="no-js "lang="en-US"> MedTech Innovator Selects 20 Premier Startups for Annual Asia Pacific Accelerator - Medtech Alert
Thursday, November 14, 2024

MedTech Innovator Selects 20 Premier Startups for Annual Asia Pacific Accelerator

MedTech Innovator, the largest accelerator of medical device companies in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the first and only regional association to provide a unified voice for the medical technology industry, today announced the 20 companies selected to participate in the organization’s Asia Pacific Accelerator program. Each of the chosen companies will receive high-profile visibility to health care investors, stakeholders and decision-makers, as well as customized mentorship through one-on-one matching with corporate partners to help with commercialization throughout Asia Pacific.

“At MedTech Innovator, we work to identify the best and brightest disruptors the industry has to offer,” said Paul Grand, CEO of MedTech Innovator. “After a rigorous narrowing process, we are excited to announce the startups selected to participate in this year’s Asia Pacific program. It’s an honor to take part in the development of these companies and help them get their products to market with less friction. Together with our sponsors, we aim to give these startups the individualized mentorship they need to one day bring their innovation to patients in the Asia Pacific region.”

“The global pandemic has fast tracked the adoption of health care technology in the Asia Pacific region” said Harjit Gill, CEO of APACMed. “Startups form an integral part of the medical technology ecosystem in fostering innovation and developing life-changing solutions to improve access and standards of care for patients. At APACMed, nurturing medtech startups is one of the strategic pillars of our work. I would like to congratulate the companies shortlisted for this year’s Asia Pacific Accelerator program and look forward to hosting them at the MedTech Forum 2021 in October.”

“The 20 startups selected for this year’s MedTech Innovator Asia Pacific Accelerator are working on important innovations for patients in Asia Pacific,” said Tim Schmid, company group chairman, Medical Devices Asia Pacific at Johnson & Johnson. “At Johnson & Johnson we are proud to bring mentorship and expertise to these entrepreneurs, to help solve the unmet health care needs of the region and beyond.”

Over 500 companies applied for the Asia Pacific program, but only five startups from the 2021 Asia Pacific cohort will advance to compete in the Grand Finals to be held at APACMed’s MedTech Forum 2021 in Singapore from October 19-20. Attended by health care industry leaders, health care providers, and investors from across the region, the MedTech Forum will also showcase solutions from the 20 Accelerator companies. The winning company, which will be determined by audience vote, stands to win a non-dilutive cash prize and the title of the 2021 MedTech Innovator Asia Pacific Winner. In total, up to US$ 300,000 in cash prizes and awards will be given out to Accelerator companies.

MedTech Innovator’s 2021 top 20 Asia Pacific Accelerator companies include:

MedTech Innovator’s 2021 Asia Pacific program sponsors include Johnson & Johnson Medical Devices Companies, Align Technology, Nipro Medical Corporation, Oliver Healthcare Packaging, Olympus Medical Systems Group, Siemens Healthineers, Cambridge Consultants, and Enterprise Singapore. The MedTech Innovator Asia Pacific Program is held in partnership with APACMed. 

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more